176 related articles for article (PubMed ID: 17917290)
1. Improvement of dissolution properties of a new Helicobacter pylori eradicating agent (TG44) by inclusion complexation with beta-cyclodextrin.
Anzai K; Mizoguchi J; Yanagi T; Hirayama F; Arima H; Uekama K
Chem Pharm Bull (Tokyo); 2007 Oct; 55(10):1466-70. PubMed ID: 17917290
[TBL] [Abstract][Full Text] [Related]
2. Two-dimensional 13C-1H heteronuclear correlation NMR spectroscopic studies for the inclusion complex of cyclomaltoheptaose (beta-cyclodextrin) with a new Helicobacter pylori eradicating agent (TG44) in the amorphous state.
Anzai K; Kono H; Mizoguchi J; Yanagi T; Hirayama F; Arima H; Uekama K
Carbohydr Res; 2006 Mar; 341(4):499-506. PubMed ID: 16427035
[TBL] [Abstract][Full Text] [Related]
3. Theoretical study on interactions of β-cyclodextrin with Helicobacter pylori eradicating agent (TG44).
Jin X; Wang X; Ren C; Miao Y; Yi L
J Mol Model; 2011 Apr; 17(4):913-20. PubMed ID: 20607331
[TBL] [Abstract][Full Text] [Related]
4. Inclusion complex of 3,9-bis(N,N-dimethylcarbamoyloxy)-5H-benzofuro[3,2-c]quinoline-6-one (KCA-098) with heptakis(2,6-di-O-methyl)-beta-cyclodextrin: interaction and dissolution properties.
Yamada T; Imai T; Ouchi K; Otagiri M; Hirayama F; Uekama K
Chem Pharm Bull (Tokyo); 2000 Sep; 48(9):1264-9. PubMed ID: 10993223
[TBL] [Abstract][Full Text] [Related]
5. The formation of an inclusion complex between a metabolite of ginsenoside, compound K and γ-cyclodextrin and its dissolution characteristics.
Igami K; Ozawa M; Inoue S; Iohara D; Miyazaki T; Shinoda M; Anraku M; Hirayama F; Uekama K
J Pharm Pharmacol; 2016 May; 68(5):646-54. PubMed ID: 26255976
[TBL] [Abstract][Full Text] [Related]
6. Comparative study on inclusion complexation of maltosyl-beta-cyclodextrin, heptakis(2,6-di-O-methyl)-beta-cyclodextrin and beta-cyclodextrin with fucosterol in aqueous and solid state.
Acartürk F; Imai T; Saito H; Ishikawa M; Otagiri M
J Pharm Pharmacol; 1993 Dec; 45(12):1028-32. PubMed ID: 7908969
[TBL] [Abstract][Full Text] [Related]
7. Improvement of solubility and oral bioavailability of 2-(N-cyanoimino)-5-[(E)-4-styrylbenzylidene]-4-oxothiazolidine (FPFS-410) with antidiabetic and lipid-lowering activities in dogs by 2-hydroxypropyl-beta-cyclodextrin.
Hara T; Hirayama F; Arima H; Yamaguchi Y; Uekama K
Chem Pharm Bull (Tokyo); 2006 Mar; 54(3):344-9. PubMed ID: 16508189
[TBL] [Abstract][Full Text] [Related]
8. Effect of cyclodextrins on the solubility and stability of candesartan cilexetil in solution and solid state.
Al Omari AA; Al Omari MM; Badwan AA; Al-Sou'od KA
J Pharm Biomed Anal; 2011 Feb; 54(3):503-9. PubMed ID: 20971593
[TBL] [Abstract][Full Text] [Related]
9. Solid-state 13C nuclear magnetic resonance spectroscopic study on amorphous solid complexes of tolbutamide with 2-hydroxypropyl-alpha- and -beta-cyclodextrins.
Kimura K; Hirayama F; Arima H; Uekama K
Pharm Res; 1999 Nov; 16(11):1729-34. PubMed ID: 10571279
[TBL] [Abstract][Full Text] [Related]
10. Experimental, molecular docking investigations and bioavailability study on the inclusion complexes of finasteride and cyclodextrins.
Mady FM; Farghaly Aly U
Drug Des Devel Ther; 2017; 11():1681-1692. PubMed ID: 28652706
[TBL] [Abstract][Full Text] [Related]
11. Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process.
Jun SW; Kim MS; Kim JS; Park HJ; Lee S; Woo JS; Hwang SJ
Eur J Pharm Biopharm; 2007 Jun; 66(3):413-21. PubMed ID: 17240129
[TBL] [Abstract][Full Text] [Related]
12. Physicochemical, in silico and in vivo evaluation of a danazol-beta-cyclodextrin complex.
Jadhav GS; Vavia PR
Int J Pharm; 2008 Mar; 352(1-2):5-16. PubMed ID: 18023545
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of a novel antimicrobial agent, TG44, for treatment of Helicobacter pylori infection.
Kamoda O; Anzai K; Mizoguchi J; Shiojiri M; Yanagi T; Nishino T; Kamiya S
Antimicrob Agents Chemother; 2006 Sep; 50(9):3062-9. PubMed ID: 16940102
[TBL] [Abstract][Full Text] [Related]
14. Formulation and biological evaluation of glimepiride-cyclodextrin-polymer systems.
Ammar HO; Salama HA; Ghorab M; Mahmoud AA
Int J Pharm; 2006 Feb; 309(1-2):129-38. PubMed ID: 16377107
[TBL] [Abstract][Full Text] [Related]
15. Improved Aqueous Solubility and Antihypercholesterolemic Activity of Ezetimibe on Formulating with Hydroxypropyl-β-Cyclodextrin and Hydrophilic Auxiliary Substances.
Srivalli KM; Mishra B
AAPS PharmSciTech; 2016 Apr; 17(2):272-83. PubMed ID: 26077622
[TBL] [Abstract][Full Text] [Related]
16. Influence of modified cyclodextrins on solubility and percutaneous absorption of celecoxib through human skin.
Ventura CA; Tommasini S; Falcone A; Giannone I; Paolino D; Sdrafkakis V; Mondello MR; Puglisi G
Int J Pharm; 2006 May; 314(1):37-45. PubMed ID: 16581211
[TBL] [Abstract][Full Text] [Related]
17. Effects of aging on crystallization, dissolution and absorption characteristics of amorphous tolbutamide-2-hydroxypropyl-beta-cyclodextrin complex.
Kimura K; Hirayama F; Arima H; Uekama K
Chem Pharm Bull (Tokyo); 2000 May; 48(5):646-50. PubMed ID: 10823700
[TBL] [Abstract][Full Text] [Related]
18. Inclusion Complexation of Etodolac with Hydroxypropyl-beta-cyclodextrin and Auxiliary Agents: Formulation Characterization and Molecular Modeling Studies.
Sherje AP; Kulkarni V; Murahari M; Nayak UY; Bhat P; Suvarna V; Dravyakar B
Mol Pharm; 2017 Apr; 14(4):1231-1242. PubMed ID: 28248111
[TBL] [Abstract][Full Text] [Related]
19. Utility of 2-hydroxypropyl-beta-cyclodextrin in an intramuscular injectable preparation of nimodipine.
Yoshida A; Yamamoto M; Itoh T; Irie T; Hirayama F; Uekama K
Chem Pharm Bull (Tokyo); 1990 Jan; 38(1):176-9. PubMed ID: 2337940
[TBL] [Abstract][Full Text] [Related]
20. Solid dispersion of hydroxypropyl beta-cyclodextrin and ketorolac: enhancement of in-vitro dissolution rates, improvement in anti-inflammatory activity and reduction in ulcerogenicity in rats.
Nagarsenker MS; Meshram RN; Ramprakash G
J Pharm Pharmacol; 2000 Aug; 52(8):949-56. PubMed ID: 11007065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
